Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma: A Phase 2 Trial in the North Central Cancer Treatment Group

BACKGROUND: The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL). METHODS: Patients with relapsed or refractory MCL were eligible to receive temsirolimus 25 mg int...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ansell, Stephen M., Inwards, David J., Rowland, Kendrith M., Flynn, Patrick J., Morton, Roscoe F., Moore, Dennis F., Kaufmann, Scott H., Ghobrial, Irene, Kurtin, Paul J., Maurer, Matthew, Allmer, Christine, Witzig, Thomas E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3627208/
https://ncbi.nlm.nih.gov/pubmed/18543327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23580
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky